VXA-G1.1-104

VXA-G1.1-104 appears to be a **specific internal Vaxart code designation** for a norovirus vaccine construct, but publicly available sources do not provide enough direct information to map this exact code unambiguously to a fully characterized clinical product. Based on Vaxart's disclosed norovirus pipeline, the closely related program area involves **oral tablet, nonreplicating adenovirus 5 vectored norovirus vaccines** expressing **norovirus GI.1 VP1** and used for prevention of **norovirus acute gastroenteritis**, often with a **dsRNA adjuvant** and designed to induce **mucosal and systemic immunity**. However, because the exact identity, composition, and relationship of VXA-G1.1-104 to disclosed candidates such as VXA-G1.1-NN or next-generation GI.1 constructs are not explicitly established in the sources reviewed, this entry should be treated as a **partially unresolved code-name record** rather than a definitively matched clinical asset.